Cytokinetics Inc Cash Flow-to-Debt Ratio
Cytokinetics Inc cash flow-to-debt ratio. Cytokinetics Inc (CYTK) has a Cash Flow-to-Debt Ratio of -0.08x as of June 2026, meaning its operating cash flow of $-159.84 Million could theoretically repay 0% of its total liabilities ($2.10 Billion) in one year. Check cash flow quality index of Cytokinetics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cytokinetics Inc (2002–2025)
Cash flow-to-debt ratio of Cytokinetics Inc from 2002 to 2025. Historical debt coverage capacity for Cytokinetics Inc across 24 annual periods. Check CYTK capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Cytokinetics Inc Cash Flow-to-Debt Ratio by Year (2002–2025)
Cytokinetics Inc cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Cytokinetics Inc. For the full cash flow conversion analysis, see Cytokinetics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.24x | $-510.01 Million | $2.08 Billion | ▲ +5.0% |
| 2024 | -0.26x | $-395.89 Million | $1.54 Billion | ▲ +24.7% |
| 2023 | -0.34x | $-414.33 Million | $1.21 Billion | ▼ -28.3% |
| 2022 | -0.27x | $-299.52 Million | $1.12 Billion | ▼ -11.8% |
| 2021 | -0.24x | $-142.52 Million | $597.46 Million | ▼ -1221.4% |
| 2020 | 0.02x | $8.94 Million | $420.42 Million | ▲ +107.0% |
| 2019 | -0.30x | $-90.91 Million | $300.75 Million | ▲ +44.7% |
| 2018 | -0.55x | $-101.22 Million | $185.24 Million | ▲ +0.7% |
| 2017 | -0.55x | $-101.76 Million | $184.97 Million | ▼ -212.7% |
| 2016 | 0.49x | $36.98 Million | $75.78 Million | ▲ +366.2% |
| 2015 | 0.10x | $4.88 Million | $46.65 Million | ▲ +109.5% |
| 2014 | -1.10x | $-44.84 Million | $40.90 Million | ▼ -308.3% |
| 2013 | -0.27x | $-7.72 Million | $28.75 Million | ▲ +95.1% |
| 2012 | -5.47x | $-33.44 Million | $6.11 Million | ▲ +44.9% |
| 2011 | -9.92x | $-45.59 Million | $4.59 Million | ▼ -65.5% |
| 2010 | -6.00x | $-44.83 Million | $7.48 Million | ▼ -1608.4% |
| 2009 | 0.40x | $8.42 Million | $21.17 Million | ▲ +124.4% |
| 2008 | -1.63x | $-61.33 Million | $37.69 Million | ▼ -2902.9% |
| 2007 | -0.05x | $-3.00 Million | $55.45 Million | ▲ +92.7% |
| 2006 | -0.75x | $-47.17 Million | $63.20 Million | ▲ +66.2% |
| 2005 | -2.21x | $-39.48 Million | $17.90 Million | ▼ -33.2% |
| 2004 | -1.66x | $-34.03 Million | $20.55 Million | ▼ -740.9% |
| 2003 | -0.20x | $-30.51 Million | $154.90 Million | ▼ -3.1% |
| 2002 | -0.19x | $-22.30 Million | $116.76 Million | — |